SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:gup.ub.gu.se/249394"
 

Sökning: id:"swepub:oai:gup.ub.gu.se/249394" > Consensus report: f...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005669naa a2200793 4500
001oai:gup.ub.gu.se/249394
003SwePub
008240528s2017 | |||||||||||000 ||eng|
009oai:DiVA.org:oru-53881
0247 a https://gup.ub.gu.se/publication/2493942 URI
0247 a https://doi.org/10.1111/apt.138682 DOI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-538812 URI
040 a (SwePub)gud (SwePub)oru
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a König, Julia,d 1983-u Örebro universitet,Institutionen för medicinska vetenskaper,NGBI4 aut0 (Swepub:oru)jkg
2451 0a Consensus report: faecal microbiota transfer - clinical applications and procedures
264 c 2016-11-27
264 1a Hoboken, USA :b Wiley,c 2017
500 a Funding Agencies:Seres TherapeuticsAbbVieAstellasBiogenJanssenMSDMundipharmaTakeda Summit TherapeuticsFalkFoundationTakeda
520 a Background Faecal microbiota transplantation or transfer (FMT) aims at replacing or reinforcing the gut microbiota of a patient with the microbiota from a healthy donor. Not many controlled or randomised studies have been published evaluating the use of FMT for other diseases than Clostridium difficile infection, making it difficult for clinicians to decide on a suitable indication. To provide an expert consensus on current clinical indications, applications and methodological aspects of FMT. Well-acknowledged experts from various countries in Europe have contributed to this article. After literature review, consensus has been achieved by repetitive circulation of the statements and the full manuscript among all authors with intermittent adaptation to comments (using a modified Delphi process). Levels of evidence and agreement were rated according to the GRADE system. Consensus was defined a priori as agreement by at least 75% of the authors. Key recommendations include the use of FMT in recurrent C. difficile infection characterised by at least two previous standard treatments without persistent cure, as well as its consideration in severe and severe-complicated C. difficile infection as an alternative to total colectomy in case of early failure of antimicrobial therapy. FMT in inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS) and metabolic syndrome should only be performed in research settings. Faecal microbiota transplantation or transfer is a promising treatment for a variety of diseases in which the intestinal microbiota is disturbed. For indications other than C. difficile infection, more evidence is needed before more concrete recommendations can be made.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicin0 (SwePub)3022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicine0 (SwePub)3022 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Gastroenterologi0 (SwePub)302132 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Gastroenterology and Hepatology0 (SwePub)302132 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Farmakologi och toxikologi0 (SwePub)301022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Pharmacology and Toxicology0 (SwePub)301022 hsv//eng
653 a clostridium-difficile infection
653 a irritable-bowel-syndrome
653 a randomized
653 a controlled-trial
653 a human intestinal microbiota
653 a active
653 a ulcerative-colitis
653 a term-follow-up
653 a crohns-disease
653 a gut microbiota
653 a nasogastric tube
653 a transplantation
653 a Gastroenterology & Hepatology
653 a Pharmacology & Pharmacy
653 a arkey jm
653 a 1989
653 a jama-journal of the american medical association
653 a v262
653 a p3452
7001 a Siebenhaar, A.u Hamburg, Germany4 aut
7001 a Hogenauer, C.u Graz, Austria4 aut
7001 a Arkkila, P.u Helsinki, Finland4 aut
7001 a Nieuwdorp, Maxu Gothenburg University,Göteborgs universitet,Wallenberglaboratoriet,Wallenberg Laboratory,Amsterdam, The Netherlands; Gothenburg, Sweden4 aut0 (Swepub:gu)xnieum
7001 a Norén, Torbjörn,d 1955-u Örebro universitet,Institutionen för medicinska vetenskaper4 aut0 (Swepub:oru)trnn
7001 a Ponsioen, C. Y.u Amsterdam, The Netherlands4 aut
7001 a Rosien, U.u Hamburg, Germany4 aut
7001 a Rossen, N. G.u Amsterdam, The Netherlands4 aut
7001 a Satokari, R.u Helsinki, Finland4 aut
7001 a Stallmach, A.u Jena, Germany4 aut
7001 a de Vos, W.u Helsinki, Finland; Wageningen, The Netherlands4 aut
7001 a Keller, J.u Hamburg, Germany4 aut
7001 a Brummer, Robert Jan,d 1957-u Örebro universitet,Institutionen för medicinska vetenskaper,NGBI4 aut0 (Swepub:oru)rnbr
7102 a Örebro universitetb Institutionen för medicinska vetenskaper4 org
7730 t Alimentary Pharmacology & Therapeuticsd Hoboken, USA : Wileyg 45:2, s. 222-239q 45:2<222-239x 0269-2813x 1365-2036
8564 u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/apt.13868
8564 u https://doi.org/10.1111/apt.13868y Fulltext
8564 u https://oru.diva-portal.org/smash/get/diva2:1055385/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u https://gup.ub.gu.se/publication/249394
8564 8u https://doi.org/10.1111/apt.13868
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-53881

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy